OpenAI Acquires Orchestra Bio to Accelerate Drug Development via AI Agents
OpenAI has acquired biotech startup Orchestra Bio to integrate its AI agent technology into Rosalind, a suite of tools for life sciences researchers. The move aims to shorten the 10-15 year drug development timeline by automating tasks like study monitoring and timeline tracking. This acquisition highlights a broader trend among AI giants, including Anthropic, to expand beyond coding into scientific applications and critical industries.